semaglutide 7.2 mg clinical trial versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b clinical trial semaglutide 2·4 mg

Ozempic is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus treatment Nausea typically appears during the first week and often improves over two to four weeks Side effects arise because semaglutide slows gastric emptying and affects gastrointestinal motility Gradual dose escalation starting at 0.25 mg weekly helps minimise severity and onset of side effects Severe abdominal pain, persistent vomiting, or signs of dehydration require prompt medical attention NICE recommends reviewing GLP-1 therapy at 6 months to assess response and tolerability Table of Contents When Do Ozempic Side Effects Typically Start

Common side effects typically improve as your body gets used to each dose level

Glucagon-like peptide 1 receptor agonists (GLP-1RAs), traditionally used in the treatment of type 2 diabetes, are becoming increasingly appreciated for their diverse applications

Novo Nordisk, the manufacturer of Ozempic and Wegovy, provided the following statement to the BBC

However, Ozempic is not approved for weight loss